Andrew Assaf, MD
Interventional Cardiology · Longview, TXNPI 1508214321
Payments from drug & device makers
Across 215 payments — averaging $69.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$1K
- Inari Medical, Inc.$986
- Shockwave Medical, Inc$659
- Amgen$598
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$520
- plus $4K from 24 others
What the payments were for
- Travel & lodging$2,78719%
- Food & beverage$11,44177%
- Education$6444%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 80 | $6,515 |
| Medtronic(2 entities) | 11 | $1,171 |
| Inari Medical, Inc. | 6 | $986 |
| Shockwave Medical, Inc | 11 | $659 |
| Amgen | 5 | $598 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $520 |
| Edwards Lifesciences | 7 | $479 |
| Boston Scientific | 7 | $447 |
| Abiomed | 5 | $432 |
| Penumbra, Inc. | 4 | $327 |
| Johnson & Johnson | 17 | $278 |
| Novartis | 3 | $266 |
| Heartflow, Inc. | 3 | $264 |
| Cardiovascular Systems Inc. | 2 | $255 |
| Opsens Inc. | 9 | $208 |
| E.r. Squibb & Sons, L.L.C. | 7 | $189 |
| Philips North America LLC | 2 | $185 |
| W. L. Gore & Associates, Inc. | 4 | $182 |
| Stryker | 2 | $152 |
| Sanofi | 1 | $150 |
| Merck | 2 | $137 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $119 |
| Chiesi USA, Inc. | 2 | $96 |
| Pfizer | 4 | $53 |
| AstraZeneca | 2 | $27 |
| Angiodynamics, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Cordis US CORP. | 1 | $17 |
| Truvic Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Perclose ProStyle$1,526
- OPTIS$1,258
- FLOWTRIEVER CATHETER, S$966
- CT THROMBECTOMY SYSTEM KIT$966
- Repatha$598
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$410
- HawkOne$361
- IN.PACT Admiral$357
- CardioMEMS HF System$308
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$301
- Impella$278
- COREVALVE EVOLUT R$248
- XIENCE SIERRA$232
- SUPERA$219
- FFRct$216
- HeartMate 3 Left Ventricular Dev$172
- GENERAL VASCULAR ACCESS$162
- Edwards SAPIEN 3 Transcatheter Heart Valve$160
- FABRAZYME$150
- Diamondback Coronary$148
How this compares
$14,886 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $28,272 |
| OzempicSemaglutide | 15 | $22,696 |
| FarxigaDapagliflozin Propanediol | 22 | $20,798 |
| JardianceEmpagliflozin | 11 | $13,778 |
| Rosuvastatin Calcium | 154 | $2,037 |
| Ranolazine ErRanolazine | 17 | $1,827 |
| Bumetanide | 33 | $936 |
| Carvedilol | 100 | $838 |
| Potassium Chloride | 39 | $721 |
| Metoprolol Succinate | 65 | $677 |
| ClopidogrelClopidogrel Bisulfate | 52 | $602 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 38 | $582 |
| Prasugrel Hcl | 15 | $541 |
| Ezetimibe | 19 | $474 |
| Losartan Potassium | 40 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $28,27228 claims |
| AstraZenecaFarxiga | $27 | $20,79822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Longview
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.